Naltrexone/Bupropion Cardiovascular Outcomes Study

Phase 4

Terminated

Conditions: Obesity
Cardiovascular Diseases

Interventions: Drug: Naltrexone HCl/Bupropion HCl ER
Drug: Placebo

Registration Number: NCT02638129

Lead Sponsor: Orexigen Therapeutics, Inc

Brief Summary: The purpose of this study is to evaluate cardiovascular (CV) safety of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) compared with placebo and rule out excess risk of major adverse cardiovascular events (MACE) when given in combination with standard of care in overweight and obese participants with documented history of CV disease.

Detailed Description: The drug being evaluated in this study is naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB). NB is being evaluated in this study to rule out excess cardiovascular risk. This study will evaluate the occurrence of major adverse CV events in participants who take NB compared with placebo given in combination with standard of care in overweight and obese participants with documented history of CV disease.

The study will enroll approximately 8800 patients. After a 2-week lead-in period evaluating tolerance to NB (participants were randomly assigned in a 1:1 ratio to 1 week of NB \[1 tablet per day\] followed by 1 week of placebo \[1 tablet per day\] or 1 week of placebo followed by 1 week of NB), participants will be randomly assigned to one of two treatment groups in a 1:1 ratio, which will remain undisclosed to the patient, study site personnel, and investigator/study physician during the study (unless there is an urgent medical need):

* Naltrexone HCl 8 mg/bupropion 90 mg extended release combination tablets

* Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants will be asked to take tablet(s) in the AM and PM at the same time each day throughout the study.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is up to 6 years. Participants will make multiple visits to the clinic, and will be contacted by telephone 30 days after last dose of study drug for a follow-up assessment.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 67

Inclusion Criteria

In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
Participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
Has body mass index (BMI) ≥27.0 kg/m^2 at Screening. 4. Is male or female and aged ≥18 years at Screening. 5. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent through 12 weeks after the last dose of study medication.
Participant meets at least 1 the following categories of cardiovascular (CV) disease (a-c):
Documented coronary artery disease (at least 1 of the following 2 criteria must be satisfied):
1. A documented history of myocardial infarction (MI) occurring greater than 3 months prior to Screening.
2. History of coronary revascularization with at least 1 of the following:
  1. Coronary artery bypass graft surgery occurring greater than 3 months prior to Screening.
  2. Percutaneous coronary intervention (PCI) occurring greater than 3 months prior to Screening.
Documented peripheral arterial disease (at least 1 of the following 3 criteria must be satisfied):
1. Current intermittent claudication or verified ischemic ulcer(s) together with documented ankle-brachial index ≤0.85.
2. History of previous vascular intervention for intermittent claudication or resting limb ischemia greater than 3 months prior to Screening (example: amputation for arterial disease, peripheral bypass, or history of angioplasty/stenting).
3. History of symptomatic carotid artery disease (requiring revascularization with carotid endarterectomy or stenting) greater than 3 months prior to Screening or ≥50% stenosis on at least one carotid artery documented by duplex ultrasonography, magnetic resonance angiography, computed tomographic angiography, or catheter-based contrast angiography.
Documented cerebrovascular disease (at least 1 of the following 2 criteria must be satisfied):
1. A history of transient ischemic attack confirmed by a neurologist greater than 3 months prior to Screening and clinically and neurologically stable at Screening.
2. A history of ischemic stroke (with a Modified Rankin Scale Score ≤3) greater than 3 months prior to Screening and clinically and neurologically stable at Screening.

Exclusion Criteria

Has received any investigational compound or investigational device within 3 months prior to Screening.
Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
Has had an MI or unstable angina within 3 months of Screening.
Has planned bariatric surgery, cardiac surgery, coronary revascularization, or peripheral artery revascularization.
Has history of bariatric surgery (eg, Roux-en-Y gastric bypass, duodenal switch, or sleeve gastrectomy).
Has had a procedure for weight loss other than bariatric surgery (eg, gastric banding or any other devices that maybe used in obesity treatment) within past 12 months prior to Screening.
Has a history of hypersensitivity or allergies to any component of naltrexone hydrochloride (HCl) and bupropion HCl extended release combination (NB) or excipients.
Has a history of cancer that has been in remission for <5 years prior to Screening. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed.
Is hemodynamically unstable, including severe heart failure (New York Heart Association Class IV) at Screening.
Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 2 years prior to Screening.
Has been randomized into a previous NB (Contrave) study or has been exposed to commercially available NB (Contrave) for any period of time prior to Screening.
Is taking excluded medications within 28 days of Screening.
Has uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mm Hg and/or ≥100 mm Hg diastolic blood pressure (DBP) on the average of two seated blood pressure measurements after being at rest at least 5 minutes, confirmed on 2 separate days during the Screening Period.
Has severe renal impairment defined by estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m^2 based on the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) at Screening.
Has a clinical history of liver failure.
Has a known infection with human immunodeficiency virus that is being treated with ritonavir, lopinavir or efavirenz.
Has known acute hepatitis at Screening.
Has chronic use of opioids, defined as longer than 3 months prior to Screening.
Has a positive drug screen for cocaine, methamphetamine, methadone, opiates, oxycodone, phencyclidine, and propoxyphene at Screening. A positive screen for amphetamines, barbiturates, benzodiazepines, and cannabinoids is exclusionary if abuse or dependence is suspected.
Has a history of seizures (including febrile seizures), cranial trauma, or other conditions that predispose the participant to seizures.
Has a history of mania, history of or current diagnosis of bipolar disorder or current diagnosis of active psychosis, active bulimia or anorexia nervosa (binge eating disorder is not exclusionary).
Is at risk for suicide attempts based on the judgment of the investigator.
If female, the participant is pregnant (confirmed by laboratory testing at screening) or lactating or intending to become pregnant from signing the informed consent through 12 weeks after last dose of study medication; or intending to donate ova during such time period.
Has a history of severe ischemic stroke (with a Modified Rankin Scale Score ≥4).
Has any major illness or condition that, in the investigator's opinion, prohibits the participant from participating in the study or meeting the planned visit schedule.
Is unable to understand verbal or written English or any other language, for which a certified translation of the approved informed consent is available.

Additional exclusion criteria to be assessed at Visit3 prior to Randomization:

Participant takes <75% or >125% of the Lead-in study medication.
Participant discontinues study medication treatment or has a known major adverse cardiovascular events (MACE) reported by investigator during the Double-Blind Lead-in Period.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lead-In: Naltrexone/Bupropion + Placebo	Naltrexone HCl/Bupropion HCl ER	Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
Lead-In: Placebo + Naltrexone/Bupropion	Naltrexone HCl/Bupropion HCl ER	Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
Lead-In: Placebo + Naltrexone/Bupropion	Placebo	Naltrexone/bupropion placebo-matching tablets, orally, once daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, once daily, for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.
Naltrexone/Bupropion	Naltrexone HCl/Bupropion HCl ER	Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet, in the morning (AM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, one tablet in the AM and one in the evening (PM), daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
Placebo	Placebo	Naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, one tablet in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and one in the PM, daily, for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, two tablets in the AM and two in the PM, daily, for up to 6 years.
Lead-In: Naltrexone/Bupropion + Placebo	Placebo	Naltrexone hydrochloride (HCl) 8 mg/bupropion HCl 90 mg extended release (ER) combination tablets, orally, once daily for 1 week, followed by naltrexone/bupropion placebo-matching tablets, orally, once daily for 1 week. Participants who tolerate the naltrexone/bupropion treatment and comply with taking the study medication during the Lead-In Period will be randomized to the Double-Blind Treatment Period.

Primary Outcome Measures

Name	Time	Method
Time From Treatment Period Randomization to the First Confirmed Occurrence of Major Adverse Cardiovascular Events (MACE)	Day 1 to first confirmed occurrence of MACE (up to 6 years)	MACE are defined as cardiovascular death, nonfatal myocardial infarction and nonfatal stroke.

Secondary Outcome Measures

Name	Time	Method
Time From Treatment Period Randomization to the First Confirmed Occurrence of Extended Major Adverse Cardiovascular Events (MACE)	Day 1 to first confirmed occurrence of extended MACE (up to 6 years)	Extended MACE defined as cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and unstable angina requiring hospitalization.
Time From Treatment Period Randomization to the Occurrence of All-Cause Death	Day 1 to the occurrence of all-cause death (up to 6 years)
Time From Treatment Period Randomization to the Occurrence of Cardiovascular Death	Day 1 to the occurrence of cardiovascular death (up to 6 years)